Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709784 · ClinicalTrials.gov registry record
Spinraza in Adult Spinal Muscular Atrophy
A clinical trial of Spinal Muscular Atrophy and Spinal Muscular Atrophy Type 3, sponsored by Washington University School of Medicine.
- Active
- Registry status
- 148
- Enrollment target
- 11
- Study locations
NCT03709784 is a study of Spinal Muscular Atrophy and Spinal Muscular Atrophy Type 3 that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 148 participants, above the 102-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (45% higher). The trial reports 11 study locations across 11 states.
The verdict
NCT03709784, a study of Spinal Muscular Atrophy and Spinal Muscular Atrophy Type 3, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 148 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a longitudinal, observational study of adult patients with genetically confirmed chromosome 5q SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
Conditions Studied
Interventions
- DRUG Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care
- OTHER One time survey
Study Locations (11)
Arizona
- Barrow Neurological Institute - Phoenix
District of Columbia
- Georgetown University - Washington D.C.
Maryland
- Johns Hopkins - Baltimore
Massachusetts
- Massachusetts General Hospital-Harvard University - Boston
Michigan
- Memorial Healthcare - Owosso
Missouri
- Washington University School of Medicine - St Louis
New York
- New York University School of Medicine - New York
Texas
- Houston Methodist Neurological Institute - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2018-08-16 |
| Est. Completion | 2025-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03709784
The ClinicalTrials.gov registry entry for NCT03709784 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 22 other Spinal Muscular Atrophy trials with a reported enrollment target (45% higher). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Spinal Muscular Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care is the first listed.
NCT03709784 reports 11 study locations spanning 11 distinct geographic areas - top geographies include Arizona, District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03709784 about?
NCT03709784 is a clinical study titled "Spinraza in Adult Spinal Muscular Atrophy". This is a longitudinal, observational study of adult patients with genetically confirmed chromosome 5q SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.
What is the current status of trial NCT03709784?
This trial is currently active not recruiting. The enrollment target is 148 participants. The study started on 2018-08-16. Estimated completion is 2025-01-01.
What conditions does trial NCT03709784 study?
This clinical trial studies the following conditions: Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type II.
What interventions are being tested in trial NCT03709784?
The interventions under investigation include: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care (DRUG), One time survey (OTHER).
Who is sponsoring clinical trial NCT03709784?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03709784 being conducted?
This trial has 11 study locations across Arizona, District of Columbia, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Muscular Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
RECRUITING
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
RECRUITING · NA
-
Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
RECRUITING · NA
-
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
RECRUITING · Phase 2
-
Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.